XML 51 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
SEGMENT INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2017
Segment Reporting [Abstract]  
Information About Reportable Segments and Reconciliation of Segment Net Sales to Consolidated Net Sales and Segment Pre-Tax Income to Consolidated Pre-Tax Income
The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 
Three Months Ended   
September 30,
 
Nine Months Ended   
September 30,
 
2017
 
2016
 
2017
 
2016
Segment Net Sales
 

 
 

 
 

 
 

United States
$
470.4

 
$
417.1

 
$
1,413.9

 
$
1,194.2

Europe
167.8

 
171.2

 
614.3

 
556.3

Japan
84.0

 
68.1

 
257.1

 
203.8

Rest of World
87.1

 
72.4

 
261.4

 
220.9

Total segment net sales
$
809.3

 
$
728.8

 
$
2,546.7

 
$
2,175.2

Segment Pre-tax Income
 

 
 

 
 

 
 

United States
$
303.2

 
$
274.2

 
$
921.4

 
$
776.0

Europe
75.3

 
80.1

 
306.9

 
273.0

Japan
46.4

 
33.4

 
145.2

 
101.5

Rest of World
24.7

 
17.4

 
77.4

 
54.4

Total segment pre-tax income
$
449.6

 
$
405.1

 
$
1,450.9

 
$
1,204.9


The table below presents reconciliations of segment net sales to consolidated net sales and segment pre-tax income to consolidated pre-tax income (in millions):
 
Three Months Ended   
September 30,
 
Nine Months Ended   
September 30,
 
2017
 
2016
 
2017
 
2016
Net Sales Reconciliation
 

 
 

 
 

 
 

Segment net sales
$
809.3

 
$
728.8

 
$
2,546.7

 
$
2,175.2

Foreign currency
12.2

 
10.6

 
0.1

 
20.8

Consolidated net sales
$
821.5

 
$
739.4

 
$
2,546.8

 
$
2,196.0

Pre-tax Income Reconciliation
 

 
 

 
 

 
 

Segment pre-tax income
$
449.6

 
$
405.1

 
$
1,450.9

 
$
1,204.9

Unallocated amounts:
 

 
 

 
 

 
 

Corporate items
(217.3
)
 
(211.9
)
 
(660.6
)
 
(613.4
)
Special charges (Note 3)
(10.2
)
 
—

 
(41.4
)
 
(34.5
)
Intellectual property litigation expenses
(13.7
)
 
(6.5
)
 
(31.6
)
 
(27.8
)
Interest expense, net
(0.1
)
 
(2.1
)
 
(3.9
)
 
(6.9
)
Foreign currency
3.5

 
0.6

 
(2.4
)
 
15.2

Consolidated pre-tax income
$
211.8

 
$
185.2

 
$
711.0

 
$
537.5
Enterprise-Wide Information
Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.
 
Three Months Ended   
September 30,
 
Nine Months Ended   
September 30,
 
2017
 
2016
 
2017
 
2016
 
(in millions)
 
 
 
 
Net Sales by Geographic Area
 

 
 

 
 

 
 

United States
$
470.4

 
$
417.1

 
$
1,413.9

 
$
1,194.2

Europe
182.3

 
172.3

 
627.0

 
564.4

Japan
83.2

 
79.8

 
253.0

 
226.3

Rest of World
85.6

 
70.2

 
252.9

 
211.1

 
$
821.5

 
$
739.4

 
$
2,546.8

 
$
2,196.0

Net Sales by Major Product and Service Area
 

 
 

 
 

 
 

Transcatheter Heart Valve Therapy
$
481.2

 
$
410.1

 
$
1,507.9

 
$
1,196.5

Surgical Heart Valve Therapy
195.6

 
190.9

 
602.2

 
585.5

Critical Care
144.7

 
138.4

 
436.7

 
414.0

 
$
821.5

 
$
739.4

 
$
2,546.8

 
$
2,196.0


 
September 30, 2017
 
December 31, 2016
 
(in millions)
Long-lived Tangible Assets by Geographic Area
 

 
 

United States
$
595.9

 
$
555.5

Europe
29.7

 
27.9

Japan
7.2

 
8.0

Rest of World
122.9

 
108.6

 
$
755.7

 
$
700.0